Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients

Area of Science:

• Immunology
• Neuroscience
• Hematology

Background:

• Multiple sclerosis (MS) is a chronic neurological disease with complex immune dysregulation.
• Abnormal microRNA and gene expression patterns are observed in MS, serving as potential biomarkers.
• Autologous hematopoietic stem cell transplantation (AHSCT) is explored as a therapeutic option for MS, but underlying mechanisms require elucidation.

Purpose of the Study:

• To investigate T- and B-cell reconstitution post-AHSCT in MS patients.
• To analyze microRNA and immunoregulatory gene expression changes following AHSCT.
• To understand the immunomodulatory mechanisms contributing to clinical remission after AHSCT.

Main Methods:

• Flow cytometry was used to assess T- and B-cell populations, including regulatory T cells (Tregs) and exhausted T cells.
• Quantitative real-time PCR was employed to measure the expression levels of specific microRNAs (miR-16, miR-155, miR-142-3p) and genes (FOXP3, FOXO1, PDCD1, IRF2BP2).
• Patient samples were analyzed at baseline, and at 6 months and 2 years post-AHSCT, with comparisons to healthy controls.

Main Results:

• AHSCT promoted early immune reconstitution driven by peripheral homeostatic proliferation.
• Post-transplantation, there was an increase in regulatory T cells (CD4(+)CD25(hi)FoxP3(+)) and associated molecules (CTLA-4, GITR), alongside transient increases in exhausted and suppressive T cells.
• MS patients showed altered baseline microRNA and gene expression, which normalized towards control levels at 6 months to 2 years post-AHSCT.

Conclusions:

• AHSCT effectively normalizes aberrant microRNA and gene expression profiles in MS patients.
• The observed changes in immune cell populations and expression patterns suggest a restoration of the immunoregulatory network.
• These immunomodulatory effects of AHSCT are likely crucial for early disease control in multiple sclerosis.